学习与工作经历：

从事泌尿外科工作20余年，目前担任山东省立医院东院泌尿微创二科主任，泌尿外科主任医师，主要从事泌尿系肿瘤的微创治疗和相关基础研究，擅长机器人辅助腹腔镜下肾肿瘤肾部分切除术和前列腺癌根治术。曾作为访问学者赴美国约翰霍普金斯医院学习，先后多次参加北京大学泌尿外科医师培训学院将才工程培训班，赴美国南加州大学、休斯敦MD Anderson医院、旧金山医院学习交流 。

研究方向：

肾癌、前列腺癌发病机制的研究，尤其是肾癌与脂代谢方面的相关研究。

学术/社会兼职：

山东省医学会泌尿外科分会委员

山东省医师协会泌尿外科分会委员

山东省中西医结合学会泌尿外科分会副主任委员

山东省疼痛研究会泌尿生殖专业委员会主任委员

山东省心功能研究会泌尿生殖专业委员会副主任委员

中国医师学会泌尿外科分会肿瘤学组委员

中国中西医结合学会泌尿外科分会前列腺学组委员

美国泌尿外科学会AUA国际会员

获奖荣誉：

山东大学青年教师讲课比赛三等奖

山东省立医院十佳青年医师

优秀创新团队

优秀住院医师指导

本科生课程：

临床医学

研究生课程：

泌尿外科学

1.82072816；LXRα/IGFBP1通过抑制CPT1A稳定内质网应激促进肾透明细胞癌增殖和转移的作用机制；国自然面上项目；2021.01-2024.12；55万元；主持

2.81672553；丙戊酸钠调控TGFβ-SMAD4信号通路抑制前列腺癌上皮间质转化的机制研究；国自然面上项目；2017.01-2020.12；57万元；主持

3.82272713；HIF-2α通过AUP1m6A甲基化调控肾透明细胞癌脂肪酸代谢及靶向耐药的机制研究；国自然面上项目；2023.01-2026. 12; 52万;主持

4.ZR2021LZY003;双氢青蒿素通过 METTL3 介导的 m6A 甲基化修饰促进铁死亡逆转去势抵抗性前列腺癌雄激素抵抗的机制研究；省自然联合基金；2022.01-2024.12; 15万；主持

1.Wu G, Wang Q, Xu Y, Li J, Zhang H, Qi G, Xia Q*. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist? Cell Death Dis. 2019 May 28;10(6):416.

2.Wu G, Xu Y, Wang Q, Li J, Li L, Han C, Xia Q*. FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma. Eur J Pharmacol. 2019 Nov 5;862:172637.

3.Wu G, Xu Y, Ruan N, Li J, Lv Q, Zhang Q, Chen Y, Wang Q, Xia Q*, Li Q. Genetic alteration and clinical significance of SUMOylation regulators in multiple cancer types. J Cancer. 2020 Sep 30;11(23):6823-6833.

4.Wu G, Xu Y, Li L, Li J, Ruan N, Dong J, Si Z, Xia Q*, Wang Q. Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinoma. Int J Med Sci. 2020 Oct 18;17(18):2905-2916.

5.Qi G, Lu G, Yu J, Zhao Y, Wang C, Zhang H, Xia Q*. Up-regulation of TIF1γby valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway. Eur J Pharmacol. 2019 Oct 5;860:172551.

6.Qi G, Wang C, Zhang H, Yu J, Ding F, Song Z, Xia Q*. Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk. Biosci Rep. 2020 Jul 31;40(7):BSR20191825.

7.Xu Y, Wu G, Li J, Li J, Ruan N, Ma L, Han X, Wei Y, Li L, Zhang H, Chen Y, Xia Q*. Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data. Biomed Res Int. 2020 Jan 23;2020:8283401.

8.Xu Y, Wu G, Ma X, Li J, Ruan N, Zhang Z, Cao Y, Chen Y, Zhang Q, Xia Q*. Identification of CPT1A as a prognostic biomarker and potential therapeutic target for kidney renal clear cell carcinoma and establishment of a risk signature of CPT1A-related genes. International Journal of Genomics. 2020 Aug 18;2020.

9.Xu Y, Wu G, Zhang J, Li J, Ruan N, Zhang J, Zhang Z, Chen Y, Zhang Q, Xia Q*. TRIM33 Overexpression Inhibits the Progression of Clear Cell Renal Cell Carcinoma In Vivo and In Vitro. Biomed Res Int. 2020 Aug 25;2020:8409239.

10.Xu Y, Li X, Han Y, Wang Z, Han C, Ruan N, Li J, Yu X, Xia Q*, Wu G. A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma. PPAR Res. 2020 Sep 22;2020:6937475.

11.Lan X, Lu G, Yuan C, Mao S, Jiang W, Chen Y, Jin X, Xia Q*. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. J Cancer Res Clin Oncol. 2016 Jan;142(1):177-85.

12.Lan X, Chen Y, Wang Z, Yuan C, Wang G, Lu G, Mao S, Jin X, Xia Q*.Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients. J Zhejiang Univ Sci B. 2015 Sep;16(9):743-56.

13.Wei M, Mao S, Lu G, Li L, Lan X, Huang Z, Chen Y, Zhao M, Zhao Y, Xia Q*. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. BMC Cancer. 2018 Apr 17;18(1):434.

14.Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z, Jin X, Xia Q*. Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol. 2014 May;46(5):941-6.

15.Mao S, Lu G, Lan X, Yuan C, Jiang W, Chen Y, Jin X, Xia Q*. Valproic acid inhibits epithelial-mesenchymal transition in renal cell carcinoma by decreasing SMAD4 expression. Mol Med Rep. 2017 Nov;16(5):6190-6199.

16.Li J, Wu G, Xu Y, Li J, Ruan N, Chen Y, Zhang Q, Xia Q*. Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma. Biomed Res Int. 2020 Feb 13;2020:2527643.

17.Xia Q, Sung J, Chowdhury W, Chen CL, Höti N, Shabbeer S, Carducci M, Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006 Jul 15;66(14):7237-44.

18.Xia Q, Zheng Y, Jiang W, Huang Z, Wang M, Rodriguez R, Jin X. Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells. Oncol Lett. 2016 Sep;12(3):1826-1832.

19.Chen C, Zhao W, Lu X, Ma Y, Zhang P, Wang Z, Cui Z, Xia Q. AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma. Cancer Sci. 2022 Aug;113(8):2600-2615.

20.Zhang P, Xu Y, Chen S, Wang Z, Zhao L, Chen C, Kang W, Han R, Qiu J, Wang Q, Gao H, Wu G, Xia Q. ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway. J Oncol. 2022 Jun 21;2022:2724515.

21.Wang Z, Li J, Zhang P, Zhao L, Huang B, Xu Y, Wu G, Xia Q. The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients. Front Genet. 2022 Jul 12;13:862210.

22.Wu G, Xu Y, Zhang H, Ruan Z, Zhang P, Wang Z, Gao H, Che X, Xia Q, Chen F. A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma. Bioengineered. 2021 Dec;12(1):7805-7819.